Open Wed 8:30am : 01582 842096
VioVet Insurance

MSD Lambivac Control of Pulpy Kidney

  • 50ml Bottle £16.53
  • 100ml Bottle £27.76

Selection of 2 products from

£16.53 to £27.76

Description

4 in 1 clostridial vaccine for the control of lamb dysentry, pulpy kidney, struck and tetanus. Licensed for use in sheep and pigs. Refrigerated Product. POM-VPS.

Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication.

Introduction

MSD-AH
Company name: MSD Animal Health
Address: Walton Manor
Walton
Milton Keynes
MK7 7AJ
Telephone: 01908 685685 (Customer Support Centre)
Fax: 01908 685555
Email: vet-support.uk@merck.com
Website: www.msd-animal-health.co.uk

Presentation

Suspension for injection containing per ml Clostridium perfringens beta toxoid inducing ≥ 10 IU; Clostridium perfringens epsilon toxoid inducing ≥ 5 IU; and Clostridium tetani toxoid inducing ≥ 2.5 IU. Also contains Aluminium hydroxide as an adjuvant and 0.13 mg/ml Thiomersal as preservative.

Uses

Sheep
For the active immunisation of sheep to:
-reduce clinical signs and mortality due to the toxin of Clostridium tetani (Tetanus);
-reduce mortality due to the epsilon toxin of Clostridium perfringens (Pulpy kidney);
-induce a serological response against the beta toxin of Clostridium perfringens (Struck, Lamb dysentery).
The vaccine may be used in pregnant ewes to provide passive immunisation of lambs, provided that the lambs receive sufficient immune colostrum during the first 12 hours of life, to:
-reduce clinical signs and mortality due to the toxin of Clostridium tetani (Tetanus);
-reduce mortality due to the epsilon toxin of Clostridium perfringens (Pulpy kidney);
-induce a serological response against the beta toxin of Clostridium perfringens (Lamb dysentery).
Significant levels of immunity cannot be expected until two weeks after the second dose of vaccine in the primary vaccination course.
From experience from field use, the duration of active immunity in lambs and sheep is expected to last one year. The duration of passive protection in lambs is approximately 12 weeks provided that the lambs receive sufficient immune colostrum during the first 12 hours of life.
Pigs
For active immunisation of sows against tetanus caused by Clostridium tetani.
Significant levels of immunity cannot be expected until two weeks after the second dose of vaccine in the primary vaccination course. From experience from field use, the duration of active immunity in pigs is expected to last one year.
The vaccine may be used in pregnant sows to provide passive immunisation of piglets, provided that the piglets receive sufficient immune colostrum during the first 12 hours of life, to:
-reduce clinical signs and mortality due to the toxin of Clostridium tetani (Tetanus);
-induce a serological response against the toxin of Clostridium perfringens type C (enterotoxaemia).

The duration of the passive protection in piglets is 14 days.

Dosage and administration

The vaccine should be administered by subcutaneous injection in the lateral side of the upper neck observing aseptic precautions.
Ewes and sows can be vaccinated during late pregnancy.

Sheep and lambs: 2 ml/dose.
Pigs: 5 ml/dose.
Sheep
All sheep from 3 weeks of age onwards and not previously vaccinated with Lambivac must receive two injections separated by an interval of 4-6 weeks to be completed before onset of the period of risk. Thereafter they should receive booster injections 2-3 weeks prior to identified risk periods with intervals of not more than 12 months. In adult breeding ewes these yearly booster injections should be given during the pre-lambing period, 4-6 weeks pre-lambing, to allow passive protection of lambs via colostrum.
Pigs
Two injections with an interval of at least 3 weeks between injections, the second dose to be administered at least 3 weeks before farrowing. The preferred schedule is vaccination at 6 and 3 weeks prior to the expected date of farrowing. Only a single booster dose is required in subsequent pregnancies at approximately 3-4 weeks pre-farrowing.

The vaccine bottle must be shaken well before use.
Syringes and needles must be from gamma irradiated packs or freshly sterilised by boiling for at least 20 minutes. No alcohol or other disinfectants should be used for sterilisation.

The use of an automatic vaccinator is recommended. Since the bottle is non-collapsible, a vaccinator with a vented draw-off spike or similar device must be used. The instructions supplied with such equipment should be noted and care should be taken to ensure the delivery of the full dose, particularly with the final few doses from the bottle.

Contra-indications, warnings, etc

Occasional hypersensitivity may occur.
Vaccination may result in small (<10 cm) transient injection site reactions possibly lasting for up to 3-4 months after vaccination.
Local tissue irritating effects of alhydrogel-adjuvanted vaccines reveal granulomatous inflammatory reactions consisting mainly of activated macrophages containing foamy cytoplasm, epithelioid cells, small lymphocytes and multinuclear giant cells.
Reactions similar to those described above were observed following administration of a double dose.

In any group of animals, a small number of individuals may fail to respond to vaccination as a result of immunological incompetence. Satisfactory immune responses will only be attained in healthy animals, thus it is important to avoid vaccination of animals which have an intercurrent infection or metabolic disorder.
When handling animals, stress should be avoided, particularly during the later stages of pregnancy when there is a risk of inducing abortion and metabolic disorders.
The nutritional and metabolic status of pregnant ewes is extremely important at the time of vaccination. If in doubt, advice should sought from a veterinary surgeon.
No information is available on the efficacy of the vaccine in young animals with maternally derived antibodies.
No information is available on the safety and efficacy of this vaccine with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Do not mix with any other veterinary medicinal product.
Operator warning
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Withdrawal period
Zero days.
For animal treatment only. Keep out of reach and sight of children.

Pharmaceutical precautions

Store in a refrigerator (+2°C to +8°C). Do not freeze.
Shelf-life after first opening the container: 10 hours.
Disposal advice
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

POM-VPS

Packaging Quantities

Cartons containing of 50 ml or 100 ml polyethylene multidose bottle, closed with a
combination seal.

Further information

Nil

Marketing authorisation number

Vm 01708/4509.

Presentation

Suspension for injection containing per ml Clostridium perfringens beta toxoid inducing ≥ 10 IU; Clostridium perfringens epsilon toxoid inducing ≥ 5 IU; and Clostridium tetani toxoid inducing ≥ 2.5 IU. Also contains Aluminium hydroxide as an adjuvant and 0.13 mg/ml Thiomersal as preservative.

Uses

Sheep

For the active immunisation of sheep to:

-reduce clinical signs and mortality due to the toxin of Clostridium tetani (Tetanus);

-reduce mortality due to the epsilon toxin of Clostridium perfringens (Pulpy kidney);

-induce a serological response against the beta toxin of Clostridium perfringens (Struck, Lamb dysentery).

The vaccine may be used in pregnant ewes to provide passive immunisation of lambs, provided that the lambs receive sufficient immune colostrum during the first 12 hours of life, to:

-reduce clinical signs and mortality due to the toxin of Clostridium tetani (Tetanus);

-reduce mortality due to the epsilon toxin of Clostridium perfringens (Pulpy kidney);

-induce a serological response against the beta toxin of Clostridium perfringens (Lamb dysentery).

Significant levels of immunity cannot be expected until two weeks after the second dose of vaccine in the primary vaccination course.

From experience from field use, the duration of active immunity in lambs and sheep is expected to last one year. The duration of passive protection in lambs is approximately 12 weeks provided that the lambs receive sufficient immune colostrum during the first 12 hours of life.

Pigs

For active immunisation of sows against tetanus caused by Clostridium tetani.

Significant levels of immunity cannot be expected until two weeks after the second dose of vaccine in the primary vaccination course. From experience from field use, the duration of active immunity in pigs is expected to last one year.

The vaccine may be used in pregnant sows to provide passive immunisation of piglets, provided that the piglets receive sufficient immune colostrum during the first 12 hours of life, to:

-reduce clinical signs and mortality due to the toxin of Clostridium tetani (Tetanus);

-induce a serological response against the toxin of Clostridium perfringens type C (enterotoxaemia).

The duration of the passive protection in piglets is 14 days.

Dosage and administration

The vaccine should be administered by subcutaneous injection in the lateral side of the upper neck observing aseptic precautions.

Ewes and sows can be vaccinated during late pregnancy.

Sheep and lambs: 2 ml/dose.

Pigs: 5 ml/dose.

Sheep

All sheep from 3 weeks of age onwards and not previously vaccinated with Lambivac must receive two injections separated by an interval of 4-6 weeks to be completed before onset of the period of risk. Thereafter they should receive booster injections 2-3 weeks prior to identified risk periods with intervals of not more than 12 months. In adult breeding ewes these yearly booster injections should be given during the pre-lambing period, 4-6 weeks pre-lambing, to allow passive protection of lambs via colostrum.

Pigs

Two injections with an interval of at least 3 weeks between injections, the second dose to be administered at least 3 weeks before farrowing. The preferred schedule is vaccination at 6 and 3 weeks prior to the expected date of farrowing. Only a single booster dose is required in subsequent pregnancies at approximately 3-4 weeks pre-farrowing.

The vaccine bottle must be shaken well before use.

Syringes and needles must be from gamma irradiated packs or freshly sterilised by boiling for at least 20 minutes. No alcohol or other disinfectants should be used for sterilisation.

The use of an automatic vaccinator is recommended. Since the bottle is non-collapsible, a vaccinator with a vented draw-off spike or similar device must be used. The instructions supplied with such equipment should be noted and care should be taken to ensure the delivery of the full dose, particularly with the final few doses from the bottle.

Contra-indications, warnings, etc

Occasional hypersensitivity may occur.

Vaccination may result in small (<10 cm) transient injection site reactions possibly lasting for up to 3-4 months after vaccination.

Local tissue irritating effects of alhydrogel-adjuvanted vaccines reveal granulomatous inflammatory reactions consisting mainly of activated macrophages containing foamy cytoplasm, epithelioid cells, small lymphocytes and multinuclear giant cells.

Reactions similar to those described above were observed following administration of a double dose.

In any group of animals, a small number of individuals may fail to respond to vaccination as a result of immunological incompetence. Satisfactory immune responses will only be attained in healthy animals, thus it is important to avoid vaccination of animals which have an intercurrent infection or metabolic disorder.

When handling animals, stress should be avoided, particularly during the later stages of pregnancy when there is a risk of inducing abortion and metabolic disorders.

The nutritional and metabolic status of pregnant ewes is extremely important at the time of vaccination. If in doubt, advice should sought from a veterinary surgeon.

No information is available on the efficacy of the vaccine in young animals with maternally derived antibodies.

No information is available on the safety and efficacy of this vaccine with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Do not mix with any other veterinary medicinal product.

Operator warning

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Withdrawal period

Zero days.

For animal treatment only. Keep out of reach and sight of children.

Pharmaceutical precautions

Store in a refrigerator (+2°C to +8°C). Do not freeze.

Shelf-life after first opening the container: 10 hours.

Disposal advice

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Legal category

POM-VPS

Packaging Quantities

Cartons containing of 50 ml or 100 ml polyethylene multidose bottle, closed with a combination seal.

Further information

Nil

Marketing authorisation number

Vm 01708/4509.

Need help or advice? Contact us:

  • Landline: 01582 842096
  • Freephone*: 0800 084 2608
  • Mon - Fri: 8:30am - 6:00pm
  • Sat: 9:00am - 1:00pm
  • Email: support@viovet.co.uk

All prices include VAT where applicable. *The freephone number is free from most UK landlines only, mobiles are usually charged so we'd recommend calling our landline from your mobile or internationally.

Reviews of MSD Lambivac Control of Pulpy Kidney

Read our customers' reviews of MSD Lambivac Control of Pulpy Kidney

Questions & Answers for MSD Lambivac Control of Pulpy Kidney

There are currently no questions for MSD Lambivac Control of Pulpy Kidney - be the first to ask one!

Ask A Question